Oncology

Latest News

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com
COA 2025: Insight, Innovation, and Independent Strength

May 5th 2025

The 2025 Community Oncology Conference empowered attendees with insights on advocacy, innovation, and practical strategies for enhancing community cancer care.

COA logo | Image Credit: © Amy Kinnamon
Community Oncology Reacts to Trump's Drug Pricing Executive Order

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com
5 Things You Should Know About Skin Cancer

May 2nd 2025

stethoscopewithcompass | Image Credit: © Talaj-stock.adobe.com
Patient Navigation Is Nonnegotiable in Cancer Care

May 1st 2025

Liver cancer - Sebastian Kaulitzki - stock.adobe.com.jpg
Elevated HLA-G Seen in HCC Driven by Viral Infections, Fatty Liver

May 1st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
October 23rd 2014

Collaborative Model Succeeds in Reducing Cancer Patient Readmissions

Oncologists and palliative care specialists at Duke University Hospital worked together in patient care, resulting in a 23% reduction in patient readmission within a week of discharge.
Site Logo
October 22nd 2014

Everolimus Under FDA Scrutiny For Potential Risk

Everolimus has been added to FDA's Adverse Event Reporting System due to a possible risk of hypertension.
Site Logo
October 21st 2014

Fast Track for Taiho Oncology's mCRC Molecule

Taiho Oncology, Inc, announced that the FDA granted Fast Track designation for an oral combination anticancer drug under investigation for the treatment of refractory metastatic colorectal cancer.
Site Logo
October 21st 2014

In the Literature: New Lead in Treating ALL

The paper, published in Nature, has identified a "switch" that can be inhibited to restrict tumor growth.
Site Logo
October 20th 2014

A SNP That Affords Protection From Breast Cancer Identified

The study, published in the journal Nature Communications, identified the single nucleotide polymorphism near the coding region of the estrogen receptor ESR1 among Latina women.
Site Logo
October 20th 2014

Including Panobinostat Improves PFS in Multiple Myeloma

Including panobinostat in a regimen that included bortezomib and dexamethasone improved median PFS to 11.9 months as compared with 8.08 months in the control arm.
Site Logo
October 19th 2014

Success of Medicare's Prescription-Subsidy Program Among Low-Income Women

A study presented at ASCO's Quality Care Symposium in Boston found increased medication adherence to prevent breast cancer recurrence in those availing of the subsidies.
Site Logo
October 18th 2014

CMS Issues Draft Coverage Decision For Prostate Cancer Test by GenomeDX

The Decipher test is intended for use in men who have undergone radical prostatectomy and are at a high risk of disease recurrence.
Site Logo
October 18th 2014

Janssen's Imbruvica Approved by the European Commission

Imbruvica (ibrutinib) is a first-in-class BTK inhibitor with potential for treating blood cancer, indicated for use in MCL and CLL patients.
Site Logo
October 18th 2014

Exact Sciences' Cologuard Receives CMS National Coverage

The non-invasive nature of the test makes it a very attractive alternative to the uncomfortable colonoscopy used to detect colorectal cancer. In a New England Journal of Medicine study of 10,000 patients, the test identified 92% of colorectal cancers in average-risk patients and 42% of polyps.
Site Logo
October 17th 2014

Roche Joins the Immuno-oncology Front With a PD-L1 inhibitor

While the current approved immuno-oncolgy drugs have been approved for melanoma, Roche has also been evaluating their new molecule in triple-negative breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium.
Site Logo
October 16th 2014

Exciting Clinical Results With Novartis' Leukemia Immune Therapy

The regimen, based on reprogramming the patient's immune T cells to attack the cancer cells, led to the disappearance of cancer in 90 percent of patients, according to a study published in the New England Journal of Medicine.
Site Logo
October 15th 2014

After Roche, Celgene Faces Value Push-Back From NICE

After Roche saw 2 product rejects a few weeks back from NICE, based on a value argument, Celgene is in a similar boat with it's multiple myeloma drug pomalidomide.
Site Logo
October 14th 2014

Study Identifies Gender Bias in HPV Vaccination

Fewer than 15% of physicians routinely recommend HPV vaccination to male patients, according to the study published in the journal Cancer Epidemiology, Biomarkers & Prevention.
Site Logo
October 14th 2014

ASCO Endorses CAP/IASLC/AMP Guideline on Molecular Testing for Lung Cancer

The American Society of Clinical Oncology has endorsed the joint guidelines established by the 3 Associations to help physicians make evidence-based decisions when selecting patients to administer some of the targeted therapies developed for lung cancer.
Site Logo
October 13th 2014

Transition to Managed Care Proves Rough for Ohio Dual Eligibles, Reports Say

Mary K. Caffrey
Ohio is the latest state to experience a rough transition to managed care in its Medicaid program, according to weekend reports. Delayed payments and service disruptions to fragile patients are among the complaints. Kentucky had a similar bumpy start when it changed to Medicaid managed care in 2011, and Kansas has had many problems recently.
Site Logo
October 13th 2014

BMS' PD-1 Inhibitor, Nivolumab, to be Evaluated With Jansenn's Ibrutinib in NHL

Opdivo (nivolumab), which was approved in Japan in July 2014, is being globally developed for evaluation in non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), head and neck cancer, glioblastoma, as well as NHL.
Site Logo
October 13th 2014

Priority Review for Pfizer's Palbociclib in Patients with Advanced Breast Cancer

The NDA submitted by Pfizer requests approval of palbociclib as a first-line therapy in combination with letrozole for ER+, HER2- advanced breast cancer.
Site Logo
October 11th 2014

Immuno-oncology Innovation From Amgen Set for Priority Review

The new BiTE antibody technology developed by the company can simultaneously engage 2 different targets, which can help recruit T-cells to malignant cells, and will be evaluated in ALL patients.
Site Logo
October 11th 2014

FDA Approves Akynzeo for Chemotherapy-Associated Nausea and Vomiting

The approval follows 2 clinical trials evaluating the regimen in 1720 cancer patients receiving chemotherapy.
Site Logo
October 10th 2014

Velcade Approved For Treatment-Naïve Mantle Cell Lymphoma Patients

The approval extends the use of bortezomib beyond relapsed and refractory patients.
Site Logo
October 9th 2014

Urine Test Could Diagnose Prostate Cancer

The identification of specific RNA molecules in the urine of individuals with prostate cancer raises hope for a non-invasive test for the disease.
Site Logo
October 8th 2014

Genentech Faces Backlash Following Onco-Specialty Decision

Having decided to restrict the distribution of 3 of its top-selling oncology medications, Avastin, Rituxan, and Herceptin only through specialty pharmacies, Genentech is witnessing protests in various forms from healthcare centers.
Episode 17 - Final Thoughts on the State of Medical Oncology
October 8th 2014

Episode 17 - Final Thoughts on the State of Medical Oncology

Episode 16 - Impact of Electronic Medical Records in Oncology Practices
October 8th 2014

Episode 16 - Impact of Electronic Medical Records in Oncology Practices

Episode 15 - Quality Metrics and Patient-Reported Outcomes
October 8th 2014

Episode 15 - Quality Metrics and Patient-Reported Outcomes

Episode 14 - Quality Initiatives in Medical Oncology
October 8th 2014

Episode 14 - Quality Initiatives in Medical Oncology

Episode 13 - Patient-Centered Approach to Improve Quality
October 8th 2014

Episode 13 - Patient-Centered Approach to Improve Quality

Episode 12 - Cost Considerations and Comparative Effectiveness Research
October 8th 2014

Episode 12 - Cost Considerations and Comparative Effectiveness Research

Episode 11 - The Importance of Patient Education
October 8th 2014

Episode 11 - The Importance of Patient Education

<1
...
148149150151152153154155156
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo